Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$3.13
+2.8%
$3.63
$1.24
$4.08
$828.56M0.964.16 million shs2.60 million shs
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
$1.06
+0.5%
$1.23
$0.86
$3.78
$234.08M0.354.39 million shs2.28 million shs
Cronos Group Inc. stock logo
CRON
Cronos Group
$2.42
-2.6%
$2.09
$1.60
$2.77
$925.04M1.011.81 million shs3.75 million shs
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$12.45
-1.0%
$10.90
$6.73
$17.08
$853.01M0.026,123 shs13,435 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-2.25%-8.43%-21.24%+8.19%+104.03%
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
-3.67%+1.94%-16.00%-5.41%-60.38%
Cronos Group Inc. stock logo
CRON
Cronos Group
-1.98%-3.13%+23.38%+19.81%+2.90%
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
+1.53%+11.33%+22.49%+19.92%+57.64%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
3.9026 of 5 stars
3.52.00.04.02.60.80.6
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
2.9854 of 5 stars
3.43.00.00.02.92.50.6
Cronos Group Inc. stock logo
CRON
Cronos Group
1.1065 of 5 stars
0.03.00.00.03.30.01.3
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
2.1281 of 5 stars
3.53.00.00.01.90.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
3.00
Buy$6.75116.69% Upside
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
2.75
Moderate Buy$8.44715.89% Upside
Cronos Group Inc. stock logo
CRON
Cronos Group
0.00
N/AN/AN/A
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
3.00
Buy$30.00145.70% Upside

Current Analyst Ratings Breakdown

Latest ALLO, AKBA, PHAR, and CRON Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/13/2025
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/4/2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform
8/4/2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Neutral
6/4/2025
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$8.00
(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$160.18M5.16N/AN/A$0.11 per share28.32
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
N/AN/AN/AN/A$1.55 per shareN/A
Cronos Group Inc. stock logo
CRON
Cronos Group
$117.61M7.83$0.00 per share5,437.12$2.95 per share0.82
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$297.20M2.81$0.07 per share167.14$3.50 per share3.49
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-$69.41M-$0.17N/AN/AN/A-17.91%N/A-13.47%11/6/2025 (Estimated)
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
-$257.59M-$1.11N/AN/AN/AN/A-55.99%-42.75%11/6/2025 (Estimated)
Cronos Group Inc. stock logo
CRON
Cronos Group
$41.08M$0.0548.1080.17N/A14.19%-3.78%-3.62%N/A
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
-$11.84M-$0.13N/A407.00N/A-2.19%-3.31%-1.78%10/23/2025 (Estimated)

Latest ALLO, AKBA, PHAR, and CRON Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
-$0.28-$0.23+$0.05-$0.23N/AN/A
8/7/2025Q2 2025
Cronos Group Inc. stock logo
CRON
Cronos Group
-$0.02-$0.10-$0.08-$0.10$45.73 million$33.46 million
7/31/2025Q2 2025
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
-$0.10$0.06+$0.16$0.06$70.36 million$93.20 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
N/AN/AN/AN/AN/A
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
N/AN/AN/AN/AN/A
Cronos Group Inc. stock logo
CRON
Cronos Group
N/AN/AN/AN/AN/A
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
1.61
1.98
1.84
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
N/A
8.92
8.92
Cronos Group Inc. stock logo
CRON
Cronos Group
N/A
24.65
23.53
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
0.38
2.79
2.07

Institutional Ownership

CompanyInstitutional Ownership
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
33.92%
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
83.63%
Cronos Group Inc. stock logo
CRON
Cronos Group
8.71%
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
0.03%

Insider Ownership

CompanyInsider Ownership
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
3.00%
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
13.20%
Cronos Group Inc. stock logo
CRON
Cronos Group
6.90%
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
2.07%
CompanyEmployeesShares OutstandingFree FloatOptionable
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
430265.14 million257.19 millionOptionable
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
310221.88 million192.59 millionOptionable
Cronos Group Inc. stock logo
CRON
Cronos Group
450383.04 million356.61 millionOptionable
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
28068.51 million67.10 millionNot Optionable

Recent News About These Companies

Pharming Group NV (PHARMA.XD) - Yahoo Finance
Pharming Group N.V. Reports Strong Q2 Earnings
Pharming Group to participate in August investor conference
New Strong Buy Stocks for August 1st
High Growth Tech Stocks To Watch In Europe July 2025
Best Momentum Stocks to Buy for July 25th
New Strong Buy Stocks for July 25th

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Akebia Therapeutics stock logo

Akebia Therapeutics NASDAQ:AKBA

$3.12 +0.09 (+2.80%)
Closing price 03:59 PM Eastern
Extended Trading
$3.08 -0.04 (-1.28%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Allogene Therapeutics stock logo

Allogene Therapeutics NASDAQ:ALLO

$1.06 +0.01 (+0.48%)
Closing price 03:59 PM Eastern
Extended Trading
$1.06 +0.01 (+0.95%)
As of 04:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Cronos Group stock logo

Cronos Group NASDAQ:CRON

$2.42 -0.07 (-2.62%)
Closing price 03:59 PM Eastern
Extended Trading
$2.44 +0.02 (+0.83%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

Pharming Group stock logo

Pharming Group NASDAQ:PHAR

$12.45 -0.13 (-1.03%)
Closing price 03:59 PM Eastern
Extended Trading
$12.46 +0.01 (+0.07%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.